Summary:
- Arrowhead Pharmaceuticals is scheduled to present new clinical data regarding their investigational RNA interference (RNAi) therapeutics at the European Society of Cardiology (ESC) Congress.
- The presentation focuses on advancements in cardiovascular medicine, specifically targeting the reduction of cardiometabolic risk factors through gene silencing technology.